Application of sophoridine as anti-anxiety drug

Through the application of huaidinine, the problems of side effects and drug resistance of existing anti-anxiety drugs have been solved, which significantly improves anxiety symptoms, provides a natural and effective anti-anxiety treatment plan, which is low toxicity and high efficiency, and demonstrates the anxiety of traditional Chinese medicine outstanding efficacy in the treatment of symptoms.

CN119055645APending Publication Date: 2024-12-03SHANDONG UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202411178311.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-27
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing anti-anxiety drugs such as diazepam and buspirone have a long time of action, low response rate, large side effects, prone to drug resistance and poor patient compliance, and lack effective alternative drugs.

Method used

Using saccharin as an anti-anxiety drug, the anti-anxiety effect was verified through animal behavioral and molecular docking experiments, and combined with the binding site of GABAA receptor, significantly improve the anxiety status in mice and provide a natural, effective and low-toxic therapeutic approach. .

Benefits of technology

Soydinazine significantly improves the anxiety status of mice, increases the time, number and distance of entering the central area of ​​the open field, reduces serum anxiety factors, increases SOD and NGF content, and reduces IL-6 and TNF-α, providing new and efficient, Low toxic anti-anxiety treatment options have great research value and clinical application potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055645A_ABST
    Figure CN119055645A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of anti-anxiety drugs, and particularly relates to application of sophoridine as an anti-anxiety drug. The sophoridine is sophoridine which is chemically synthesized or sophoridine which is extracted from natural medicines and plants. The invention relates to an anti-anxiety drug. The anti-anxiety component of the anti-anxiety drug is sophoridine. The invention relates to an anti-anxiety drug. The anti-anxiety drug is prepared from sophoridine. The invention discloses an application of sophoridine as an anti-anxiety drug, which fully proves the anti-anxiety effect of sophoridine through experimental verification, changes the limitation view on the drug effect of sophoridine in the prior art, overcomes the technical prejudice, and provides a new treatment approach for anxiety patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of antianxiety drugs, and in particular relates to the application of sophoridine as antianxiety drug. Background Art

[0002] Anxiety disorder is one of the most common mental illnesses, with tension, panic, worry, fear, and autonomic dysfunction as main symptoms. It has the characteristics of high incidence and high recurrence rate, which seriously affect the quality of life of patients. It is a mental illness with persistent mental anxiety, physical anxiety, sleep disorders, etc. as its main characteristics. Its global prevalence rate is 7.3%-28%, ranking first among adult mental illnesses in my country.

[0003] With the development of my country's economy and the progress of social civilization, people have long eliminated their narrow misunderstandings about mental illness. Correct understanding has greatly increased people's attention to their own mental health. More and more people are actively seeking medical treatment due to their own anxiety symptoms. Anxiety disorders have become a common type of disease in general hospital outpatient clinics, psychological counseling and treatment institutions. More and more people with anxiety symptoms hope to receive timely and effective diagnosis and treatment. To this end, medical workers around the world are actively conducting research on the pathogenesis of anxiety disorders and prevention and treatment programs.

[0004] At present, clinical treatment mostly uses drugs such as diazepam and buspirone. These traditional antianxiety drugs have the disadvantages of long duration of action, low response rate, large side effects, easy to produce drug resistance and poor patient compliance, such as drowsiness, constipation, muscle relaxation, memory loss, drug dependence, drug tolerance, withdrawal reaction, etc. Therefore, finding antianxiety drugs with definite efficacy and small side effects has become an important content in the current antianxiety research field. Compared with Western medicine, Chinese medicine and its extracted monomers have the characteristics of significant efficacy and small side effects, and exert their unique therapeutic effects through multiple pathways, multiple targets, and multiple functions. Due to its unique advantages, it has great research value in the field of antianxiety.

[0005] Sophoridine is a natural monomeric alkaloid, a tetracyclic quinolizidine monomeric alkaloid, commonly found in plants such as Sophora alopecuroides of the Leguminosae family, and is a highly effective and low-toxic anticancer alkaloid. Its chemical formula is C15H24N2O, its molecular weight is 248.36, and its Chinese alias is matrine-15-one.

[0006] In the prior art, sophoridine is recognized to have antibacterial, antiviral, anti-inflammatory, immunomodulatory and anti-tumor effects. It is often used clinically to treat malignant tumors such as colorectal cancer, gastric cancer, pancreatic cancer, and breast cancer. In August 2005, sophoridine and its preparation, sophoridine hydrochloride injection, were approved for marketing by the State Food and Drug Administration as a new type of anti-cancer drug independently developed in my country. However, there is no literature reporting that it has an anti-anxiety effect. Summary of the invention

[0007] The invention discloses the use of sophoridine as an antianxiety drug, and through experimental verification, fully proves the antianxiety effect of sophoridine, changes the limited view on the efficacy of sophoridine in the prior art, overcomes technical prejudice, and provides a new treatment approach for patients with anxiety disorders.

[0008] To achieve the above object, the technical solution of the present invention is:

[0009] Use of sophoridine as an anxiolytic.

[0010] Preferably, the sophoridine is chemically synthesized sophoridine or sophoridine extracted from natural medicine or plants.

[0011] An antianxiety drug, wherein the antianxiety component of the antianxiety drug is sophoridine.

[0012] An antianxiety drug is prepared from sophoridine.

[0013] The beneficial effects of the application of sophoridine as an antianxiety drug of the present invention are:

[0014] 1. The present invention provides the use of sophoridine as an antianxiety drug, providing a new, reliable and efficient treatment approach for patients with anxiety disorders.

[0015] 2. Studies have shown that, in addition to its traditional anti-cancer properties, sophoridine also has important research value in anti-anxiety. Through a series of rigorous experimental studies of animal behavior genomics and molecular docking, the present invention has confirmed that it can significantly improve the anxiety of mice. Due to its naturalness, effectiveness and low toxicity, it shows great research value and demonstrates the outstanding efficacy of traditional Chinese medicine in treating anxiety.

[0016] 3. The study found that intraperitoneal injection of sophoridine can significantly improve the anxiety state of mice: the time, number and distance of mice entering the central area of ​​the open field increased significantly; the number of explorations and residence time of mice entering the open arm of the elevated plus maze increased significantly; the latency of feeding in the unfamiliar environment inhibition feeding experiment was significantly shortened. There were no adverse reactions and no deaths in the acute toxicity test and chronic toxicity test mice, and molecular docking found that sophoridine had strong binding sites with beta2, alpha1 and gamma2 subunits of GABAA receptors (GABA neurons are closely related to anti-anxiety). Biochemical experiments found that intraperitoneal injection of sophoridine can significantly change the serum anxiety factors of mice, increase the serum SOD and NGF levels of mice, and reduce the serum IL-6, TNF-α, and GSH levels. The above experiments have fully verified the anti-anxiety effect of sophoridine, which is worthy of promotion and further research and development, and is expected to bring new hope to patients with anxiety. The positive effects of anti-anxiety drugs are also of great significance in reducing the socioeconomic burden of anxiety (drug side effects, drug tolerance, and drug withdrawal reactions will aggravate the disease, cause disability, and accidents, and reduce patient compliance).

[0017] 4. The study found that the intervention concentration of sophoridine for anti-anxiety effects in mice was 20 mg / kg via intraperitoneal injection.

[0018] Instruction Manual

[0019] Figure 1 , the effect of drug treatment on the total distance traveled in the open field of mice.

[0020] Figure 2 , the effects of drug treatment on the distance traveled in the central area of ​​the open field in mice.

[0021] Figure 3 , the effect of drug treatment on the time mice stay in the central area of ​​the open field.

[0022] Figure 4 , the effect of drug treatment on the number of entries into the central area of ​​the open field by mice.

[0023] Figure 5 , the effects of drug treatment on the open arm entry time of mice in the elevated plus maze test.

[0024] Figure 6 , the effects of drug treatment on the number of entries into the open arms of the elevated plus maze test in mice.

[0025] Figure 7 , the effect of drug treatment on the time mice enter the light area in the light-dark box experiment.

[0026] Figure 8 , the effect of drug treatment on the number of times mice enter the light area in the light-dark box experiment.

[0027] Fig. 9 , the effect of drug treatment on the feeding latency of mice in the unfamiliar environment suppressed feeding experiment.

[0028] Fig.10 , test results of mouse serum SOD after drug treatment.

[0029] Fig.11 , test results of mouse serum NGF after drug treatment.

[0030] Fig.12 , test results of mouse serum IL-6 after drug treatment.

[0031] Fig.13 , test results of mouse serum TNF-α after drug treatment.

[0032] Fig.14 , test results of serum GSH in mice after drug treatment.

[0033] Fig.15 , the three-dimensional structure of protein receptors from different perspectives.

[0034] Fig.16 , the three-dimensional structure of small molecule ligand after energy optimization.

[0035] Fig.17 , Molecular docking scoring results

[0036] Fig.18 , 2 D interaction mode.

[0037] Fig.19 , 3 D interaction mode.

[0038] The English part of the picture is translated as follows:

[0039] Total distance in the open field test (Total Distance), center area distance in the open field test (Center Area Distance), time in the center area of ​​the open field test (Time in Center Area), number of entries to the center area of ​​the open field test (Number of Central Area), percentage of time in the open arm of the elevated plus maze test (OT%), percentage of open arm entries in the elevated plus maze test (OE%), time in the light area of ​​the light-dark box test (Time of Light Area), number of entries to the light area of ​​the light-dark box test (Number of Light Area), and latency to feed in a strange environment (FeedingLatency). DETAILED DESCRIPTION

[0040] The following description is only a preferred embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

[0041] The following embodiments may be understood as individually expressing a part of a local structure or method of the present invention, or may be understood as a combination of the embodiments to explain the connotation of a larger structure or method of the present invention.

[0042] Example 1

[0043] Use of sophoridine as an anxiolytic.

[0044] Example 2

[0045] Based on Example 1, this example discloses that: the sophoridine is chemically synthesized sophoridine or sophoridine extracted from natural medicine or plants.

[0046] Example 3

[0047] Based on Examples 1 and 2, this example discloses: an antianxiety drug, wherein the antianxiety component of the antianxiety drug is sophoridine.

[0048] In this embodiment, the antianxiety drug refers to an antianxiety drug prepared by adding sophoridine as a component having an antianxiety effect and necessary auxiliary components (such as auxiliary materials commonly used in traditional Chinese medicine preparations).

[0049] Example 4

[0050] Based on Examples 1 and 2, this example discloses: an antianxiety drug, wherein the antianxiety drug is prepared from sophoridine.

[0051] In this embodiment, the anti-anxiety drug is made of sophoridine monomers, including oral preparations and injections.

[0052] Example 5

[0053] In order to verify the antianxiety effect of sophoridine, this example provides an animal experiment using sophoridine as an antianxiety drug.

[0054] 1. Purpose of the experiment

[0055] Using the open field test, elevated plus maze test, light-dark box test, novel environment feeding suppression test and ELISA test, the effectiveness and scientificity of sophoridine in anti-anxiety were verified. Specifically, it was verified by three methods: (1) Experimental pharmacology method: Using healthy normal animals as experimental subjects to conduct pharmacodynamic research. (2) Biochemical analysis method: Testing the changes of serum anxiety factors. (3) Computer simulation method: Analyzing the interaction sites between sophoridine and GABAA receptor. Finally, the efficacy and mechanism of sophoridine in anti-anxiety were proved.

[0056] 2. Materials and Methods

[0057] 2.1 Materials

[0058] 2.1.1 Instruments and Consumables

[0059] SuperMaze animal behavior analysis system, open field test system, elevated plus maze test system, light-dark box test system: Shanghai Xinruan Information Technology Co., Ltd.;

[0060] 2.1.2 Drugs

[0061] Sophoridine standard: Shanghai Yuanye Bio-Technology Co., Ltd., specification: 200 mg / bottle, product number: B50585.

[0062] 2.1.3 Animals

[0063] SPF-grade male C57BL / 6J mice, body weight 20 ± 2 g, 40 mice. Provided by Beijing Vital River Laboratory Animal Technology Co., Ltd., license number: SCXK(Beijing)2021-0006.

[0064] 2.2 Methods

[0065] 2.2.1 Breeding Conditions and Grouping

[0066] Five mice were housed in one cage, with free access to food and water, and raised in a room with controlled light, temperature and humidity: temperature 21 ± 2 °C, humidity 50 ± 10%, 12 h / 12 h light-dark cycle (lights on at 20:00, lights off at 8:00). All animal experiments were conducted in accordance with the guiding principles for the welfare and use of laboratory animals promulgated by NIH. After 7 days of adaptive feeding, they were divided into 4 groups according to the random block design method (according to body weight): normal group, low-dose group, medium-dose group, high-dose group.

[0067] 2.2.2 Administration Method and Course

[0068] At 9:00 a.m. every day, the normal group was intraperitoneally injected with normal saline, the low-dose group was intraperitoneally injected with sophoridine (10 mg / kg), the medium-dose group was intraperitoneally injected with sophoridine (20 mg / kg), and the high-dose group was intraperitoneally injected with sophoridine (40 mg / kg). The intraperitoneal injection volume was 0.1 ml·10 g -1 , lasting 28 days.

[0069] 2.2.3 Experimental methods

[0070] The open field test, elevated plus maze test, light-dark box test, and unfamiliar environment inhibition of food intake test were conducted as follows:

[0071] Open field test: The experiment was conducted in an open field box with a length of 50 cm, a width of 50 cm, and a depth of 50 cm. The bottom of the open field box was divided into 9 squares, the middle area was the central area, and the remaining area was the peripheral area. The bottom and surrounding areas of the open field box were all white. The experiment was conducted in a quiet weak red light environment. At the beginning, the mice were placed in the center of the open field box, and the Supermaze software recorded the activities within 6 minutes. The test started 1 hour after the intraperitoneal injection of the drug intervention, and the total movement distance of the mice, the movement distance of the central area, the entry time, and the number of entries were recorded.

[0072] Elevated plus maze test: The experimental system includes 2 relatively open arms of 35 cm × 6 cm and 2 relatively closed arms of 35 cm × 6 cm. The upper part of the closed arms is open, and the surroundings of the open arms are open. There is a relatively open part of 5 cm × 5 cm in the middle between the open and closed arms. The maze is 50 cm above the ground. The mouse is placed in the central open part with its head facing the open arm. Supermaze software records the number of times the mouse enters the open and closed arms and the time it stays in the two arms within 5 minutes (based on the standard of all four limbs entering or exiting the arms). The test started 1 hour after the intraperitoneal injection of the drug, and the number and time of the mouse entering the open arm were calculated as a percentage (percentage) of the total number of times (the sum of the number of times in the two arms) and the total time (the sum of the time spent in the two arms).

[0073] Light-dark box experiment: The light-dark box consists of an integral box body divided into two compartments of the same size of 25cm×25cm×30cm by a 6.5cm×6.5cm middle door, namely the light area and the dark area. The light area is illuminated by white light, and the dark area is illuminated by red light. At the beginning of the experiment, each mouse was placed in the center of the light area facing the partition wall, and the middle partition door was removed. The animal's four paws entered the compartment once, which was counted as one entry. The mouse's stay time in the light area and the number of times it entered the light area within 5 minutes were recorded.

[0074] Strange environment inhibition feeding experiment: The length of time it takes for mice to take the first bite of food in a novel environment can be used to detect the mouse's responsiveness to rewards and judgment of the surrounding environment. The increased time spent on eating indicates that the mouse has a decreased responsiveness to rewards, reduced interest, slow reaction, and decreased judgment of the surrounding environment, thereby simulating human anxiety symptoms. Use a white opaque resin test box with an open top, cover the bottom with about 2 cm thick bedding, and place 6 feed pellets in the center. After fasting for 24 hours, put the mouse in the box from the same corner and start timing. The time taken to chew food is used as the standard, and the time is recorded, which is defined as the feeding latency. The test lasts a total of 5 minutes. The test starts 1 hour after the drug intervention. The feeding latency of those who have not eaten within 5 minutes is recorded as 5 minutes.

[0075] Biochemical experimental method: Mice were anesthetized with isoflurane, and eyelid reflex test was performed. After the animals entered a deep anesthesia state, blood was collected from the abdominal aorta. After the blood was allowed to stand at room temperature for 30 minutes, it was centrifuged at 3500rpm / 15min and the supernatant was stored in a -80℃ refrigerator for testing. The test was performed according to the instructions of the relevant kit. Within 5 minutes after the reaction was terminated, the concentration values ​​of each standard on the test kit were entered, and the optical density values ​​(OD) of each group were measured in turn at the specified wavelength using an enzyme marker. After obtaining the standard curve, the sample OD value was substituted into the obtained regression equation to calculate the concentration of each sample.

[0076] Molecular docking calculation method:

[0077] (1) Receptor structure preparation

[0078] Download the three-dimensional structure file of the receptor protein from the RCSB PDB database (https: / / www.rcsb.org / ), PDBID: 6X40 (Resolution: ). Pymol software was used to remove water molecules and other heteroatoms from the crystal structure, such as Fig.15 As shown, AutoDock Tools 1.5.6 was further used for hydrogenation and charge addition, and .pdbqt files were generated for docking.

[0079] (2) Ligand structure preparation

[0080] The ligand small molecule structure was drawn using ChemOffice 2019 software, and the molecular structure was optimized under the MMF94 force field for subsequent molecular docking. AutoDock Tools 1.5.6 software was used to process the ligand structure, calculate the charge and generate a .pdbqt file for molecular docking, such as Fig.16 shown.

[0081] (3) Molecular docking method

[0082] Molecular docking was performed using AutoDock vina software, and the docking parameters were set as follows: the center coordinates of the docking box (center_X, center_Y, center_Z) were set to (123.509, 112.660, 118.273), the number of grid points in each direction of XYZ was set to 126 × 126 × 76, spacing = 1, and the rest of the parameters were set to the default values. The docking results were visualized using Pymol and Ligplus software.

[0083] 2.2.4 Statistical methods

[0084] Data were analyzed using GraphPad Prism 8.01 software (GraphPad Software, Inc., San Diego, California, USA). All groups were tested for normality (Kolmogorov-Smirnov test) and homogeneity of variance (Levene test) before parameter testing. All test parameters were compared between groups using unpaired T tests (one-tailed), and the test level was set at p < 0.05.

[0085] 3. Experimental results

[0086] 3.1 Results of normal animal pharmacodynamic experiments

[0087] (1) Mouse open field test

[0088] Table 1 Results of total distance traveled by mice in the open field

[0089] Group dose Number of animals Total distance(mm) Normal group - 9 17966±1177 Low dose group 10mg / kg 10 16996±1166 Medium dose group 20mg / kg 8 16878±763.7 High dose group 40mg / kg 9 16633±1115

[0090] like Figure 1 Shown is the effect of each drug on the total distance traveled in the open field of mice 60 minutes after the last intraperitoneal injection.

[0091] In the open field experiment of mice, compared with the normal group, drug intervention in each group had no effect on the total distance traveled by mice.

[0092] Table 2 Results of the distance traveled in the central area of ​​the open field by mice

[0093] Group dose Number of animals Central area distance (mm) Normal group - 9 900.6±107.0 Low dose group 10mg / kg 10 966.6±260.4 Medium dose group 20mg / kg 8 1105±190.9* High dose group 40mg / kg 9 1266±106.8

[0094] like Figure 2 The figure shows the effect of each drug on the central area distance of mice 60 minutes after the last intraperitoneal injection. Compared with the normal group, *p<0.05.

[0095] In the open field test of mice, compared with the normal group, the medium-dose group can significantly increase the central area distance of mice.

[0096] Table 3 Results of the time mice stayed in the central area of ​​the open field

[0097] Group dose Number of animals Central area stay time (s) Normal group - 9 9.251±2.091 Low dose group 10mg / kg 10 13.10±3.071 Medium dose group 20mg / kg 8 21.50±2.928** High dose group 40mg / kg 9 18.64±4.402*

[0098] like Figure 3 The figure shows the effect of each drug on the residence time of the central area of ​​mice 60 minutes after the last intraperitoneal injection. Compared with the normal group, *p<0.05, **p<0.01.

[0099] In the open field test of mice, compared with the normal group, the medium-dose group and the high-dose group could significantly increase the time mice stayed in the central area.

[0100] Table 4 Results of the number of times mice entered the central area of ​​the open field

[0101]

[0102]

[0103] like Figure 4 Shown is the effect of each drug on the number of entries into the central zone of mice 60 minutes after the last intraperitoneal injection.

[0104] In the open field experiment of mice, compared with the normal group, drug intervention in each group had no effect on the number of times mice entered the central area.

[0105] (2) Mouse elevated plus maze test

[0106] Table 5 Results of percentage of time spent in the open arm of the elevated plus maze in mice

[0107] Group dose Number of animals OT% Normal group - 8 4.135±1.330 Low dose group 10mg / kg 6 4.052±0.8962 Medium dose group 20mg / kg 8 9.038±0.7752** High dose group 40mg / kg 6 4.756±1.704

[0108] like Figure 5 The figure shows the effect of each drug on the percentage of time spent in the open arm of the elevated plus maze in mice 60 minutes after the last intraperitoneal injection. Compared with the normal group, **p<0.01.

[0109] In the elevated plus maze test, compared with the normal group, the medium-dose group could significantly increase the percentage of time that mice entered the open arm of the elevated plus maze.

[0110] Table 6 Results of percentage of entries into the open arms of the elevated plus maze for mice

[0111] Group dose Number of animals OE% Normal group - 8 12.72±3.034 Low dose group 10mg / kg 6 10.29±1.992 Medium dose group 20mg / kg 8 19.49±1.387* High dose group 40mg / kg 6 11.98±1.478

[0112] like Figure 6The figure shows the effect of each drug on the percentage of entries into the open arm of the elevated plus maze of mice 60 minutes after the last intraperitoneal injection. Compared with the normal group, *p<0.05.

[0113] In the elevated plus maze test, compared with the normal group, the medium-dose group could significantly increase the percentage of mice entering the open arms of the elevated plus maze.

[0114] (3) Mouse light-dark box experiment

[0115] Table 7 Results of the mouse light-dark box experiment on the time of entering the light area

[0116]

[0117]

[0118] like Figure 7 The figure shows the effect of each drug on the time of entering the light area of ​​the light-dark box test in mice 60 minutes after the last intraperitoneal injection. Compared with the normal group, **p<0.01.

[0119] In the light-dark box experiment of mice, compared with the normal group, each dose group can significantly increase the time mice enter the light area of ​​the light-dark box experiment.

[0120] Table 8 Results of the mouse light-dark box experiment, the number of times the mouse entered the light area

[0121] Group dose Number of animals Number of entries Normal group - 6 7.333±0.7601 Low dose group 10mg / kg 9 9.111±1.513** Medium dose group 20mg / kg 7 10.29±0.6801** High dose group 40mg / kg 7 9.714±0.2857**

[0122] like Figure 8 The figure shows the effect of each drug on the number of entries into the light area of ​​the light-dark box test in mice 60 minutes after the last intraperitoneal injection. Compared with the normal group, **p<0.01.

[0123] In the light-dark box experiment of mice, compared with the normal group, each dose group could significantly increase the number of times mice entered the light area of ​​the light-dark box experiment.

[0124] (4) Experiment on the inhibition of food intake in mice by unfamiliar environment

[0125] Table 9 Results of latency period of mice inhibited from feeding in unfamiliar environment

[0126] Group dose Number of animals Time(s) Normal group - 10 79.44±4.637 Low dose group 10mg / kg 8 76.63±7.495 Medium dose group 20mg / kg 8 62.40±6.306* High dose group 40mg / kg 6 68.83±7.162

[0127] like Fig. 9 The figure shows the effect of each drug on the latency of mice to inhibit food intake in a strange environment 60 minutes after the last intraperitoneal injection. Compared with the normal group, *p<0.05.

[0128] In the unfamiliar environment food intake inhibition experiment, compared with the normal group, the medium-dose group can significantly reduce the unfamiliar environment food intake inhibition latency of mice.

[0129] (4) Elisa test experiment

[0130] Table 10 Mouse serum SOD test results record

[0131]

[0132]

[0133] like Fig.10 The figure shows the effect of each drug on the test results of mouse serum SOD 60 minutes after the last intraperitoneal injection. Compared with the normal group, *p<0.05, **p<0.01.

[0134] In the mouse Elisa test experiment, compared with the normal group, each dose group could significantly increase the serum SOD content of mice.

[0135] Table 11 Mouse serum NGF test results record

[0136] Group dose Number of animals Concentration (pg / ml) Normal group - 7 184.40±66.00 Low dose group 10mg / kg 8 253.3±68.83 Medium dose group 20mg / kg 8 341.7±53.51* High dose group 40mg / kg 7 236.9±42.13

[0137] like Fig.11 The figure shows the effect of each drug on the test results of mouse serum NGF 60 minutes after the last intraperitoneal injection. Compared with the normal group, *p<0.05.

[0138] In the mouse Elisa test experiment, compared with the normal group, the medium-dose group could significantly increase the serum NGF content of mice.

[0139] Table 12 Mouse serum IL-6 test results record

[0140] Group dose Number of animals Concentration (pg / ml) Normal group - 7 14.30±3.082 Low dose group 10mg / kg 8 6.023±0.7602* Medium dose group 20mg / kg 8 6.209±0.2700* High dose group 40mg / kg 7 8.325±1.664

[0141] like Fig.12 The figure shows the effect of each drug on the test results of mouse serum IL-6 60 minutes after the last intraperitoneal injection. Compared with the normal group, *p<0.05.

[0142] In the mouse Elisa test experiment, compared with the normal group, both the low-dose and medium-dose groups could significantly reduce the serum IL-6 content of mice.

[0143] Table 13 Mouse serum TNF-α test results record

[0144] Group dose Number of animals Concentration (pg / ml) Normal group - 7 162.2±45.57 Low dose group 10mg / kg 8 98.93±37.07 Medium dose group 20mg / kg 8 57.71±16.92* High dose group 40mg / kg 7 69.00±52.09

[0145] like Fig.13 The figure shows the effect of each drug on the test results of mouse serum TNF-α 60 minutes after the last intraperitoneal injection. Compared with the normal group, *p<0.05.

[0146] In the mouse Elisa test experiment, compared with the normal group, the medium-dose group could significantly reduce the TNF-α content in mouse serum.

[0147] Table 14 Mouse serum GSH test results record

[0148] Group dose Number of animals Concentration (μmol / ml) Normal group - 7 0.1079±0.02267 Low dose group 10mg / kg 8 0.06840±0.01419 Medium dose group 20mg / kg 8 0.05433±0.01195* High dose group 40mg / kg 7 0.06420±0.01264

[0149] like Fig.14 The figure shows the effect of each drug on the test results of mouse serum GSH 60 minutes after the last intraperitoneal injection. Compared with the normal group, *p<0.05.

[0150] In the mouse Elisa test experiment, compared with the normal group, the medium-dose group could significantly reduce the serum GSH content of mice.

[0151] The following conclusions can be drawn from the above experimental results:

[0152] The molecular docking results show that the most negative value of the docking score between small molecule ligand and protein receptor molecule is -5.17 ( Fig.17 ).

[0153] In order to further analyze the possible binding mechanism between small molecule ligands and protein receptors at the binding site, the most likely interaction mode between the two (the site with a score of -5.17) was analyzed, such as Fig.18 and 19 As shown. The small molecule ligand is located in the protein docking cavity (the binding site is located in the center of the protein cavity, Fig.19 ) can form interactions with nearby amino acid residues, such as the amino acid residue Thr268 of the D chain of the N atom protein of the small molecule ligand to form a hydrogen bond interaction. In addition, the ligand molecule can form hydrophobic interactions with some surrounding amino acid residues, such as Fig.18 The amino acid residues of chains A, C, D, and E are shown in FIG.

[0154] The above research results show that intraperitoneal injection of sophoridine can significantly improve the anxiety state of mice: the time and distance of mice entering the central area of ​​the open field increased significantly; the number of explorations and the time of staying in the open arm of the elevated plus maze test increased significantly; the time and number of entries into the light area of ​​the light-dark box test increased significantly; the latency of feeding in the unfamiliar environment inhibition feeding test was significantly shortened. In the mouse Elisa test experiment, intraperitoneal injection of sophoridine can significantly increase the serum SOD and NGF levels of mice, and reduce the serum IL-6, TNF-α, and GSH levels. The results of molecular docking experiments show that sophoridine can bind to the beta2, alpha1, and gamma2 subunits of the GABAA receptor to exert an anti-anxiety effect.

[0155] It should be noted that, based on Example 5, the content of sophoridine in antianxiety drugs for human use or the dosage of antianxiety drugs can be screened through limited clinical trials. The present invention can be made into antianxiety drugs in various dosage forms based on sophoridine as antianxiety component.

Claims

1. Application of sophoridine as an antianxiety drug.

2. The use according to claim 1, characterized in that: The sophoridine is chemically synthesized sophoridine or sophoridine extracted from natural medicines or plants.

3. An anti-anxiety drug, characterized in that: The antianxiety component of the antianxiety drug is sophoridine.

4. An anti-anxiety drug, characterized in that: The antianxiety drug is made from sophoridine.

Citation Information

Patent Citations

  • Application of TASa (Total Alkaloids of Sophora alopecuroides) to preparation of anti-anxiety medicine

    CN105663226A

  • Novel medicine purpose of Sophoridin

    CN108379267A